Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock GlobeNewswire - Tue Dec 9, 2025

BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 46.52 (-1.17%)
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock GlobeNewswire - Mon Dec 8, 2025

BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 46.52 (-1.17%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Dec 5, 2025

BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 46.52 (-1.17%)
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors GlobeNewswire - Wed Nov 26, 2025

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 46.52 (-1.17%)
Vera Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire - Mon Nov 24, 2025

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 46.52 (-1.17%)
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit GlobeNewswire - Mon Nov 10, 2025

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 46.52 (-1.17%)
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy GlobeNewswire - Fri Nov 7, 2025

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%...

VERA : 46.52 (-1.17%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 7, 2025

BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 46.52 (-1.17%)
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine GlobeNewswire - Thu Nov 6, 2025

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36...

VERA : 46.52 (-1.17%)
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results GlobeNewswire - Wed Nov 5, 2025

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN)...

VERA : 46.52 (-1.17%)

Barchart Exclusives

'Project Catalyst' Is Coming for This High-Yield Dividend Star. Should You Buy Shares in 2026 to Profit? Barchart - 1 hour ago
Can AI save this consumer packaged foods company from the relentless margin pressure? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot